Island Pharmaceuticals Obtains Singapore Patent for ISLA-101 Targeting Dengue and Chikungunya Viruses

Details of Singapore Patent No. 10202011533P and Its Protection for ISLA-101

The Intellectual Property Office of Singapore has formally granted a patent protecting ISLA-101’s use in treating flavivirus infections — which include Dengue — as well as Chikungunya virus infections. Importantly, the patent claims apply to ISLA-101 when used without any other antiviral agents, ensuring exclusivity for ISLA-101 as a standalone treatment rather than in combination therapies. This distinction is commercially significant as it defines a clear scope of exclusivity supporting Island’s development and licensing plans.

Named "Method of Viral Inhibition," the patent carries the reference Singapore Patent No. 10202011533P. According to Island’s announcement, the patent protection extends until 16 April 2034, providing a defined period of commercial exclusivity in Singapore. This timeframe supports the long-term development and potential commercialization of ISLA-101 across multiple viral disease indications as the company advances clinical trials.

Expanding ISLA-101’s Therapeutic Reach to Include Chikungunya

Prior to this patent approval, ISLA-101’s public focus was primarily on Dengue fever, a mosquito-borne illness affecting hundreds of millions worldwide annually. The inclusion of Chikungunya in the Singapore patent claims significantly broadens ISLA-101’s protected therapeutic scope. Like Dengue, Chikungunya is transmitted by Aedes mosquitoes and currently lacks widely approved antiviral treatments — representing both a major public health challenge and a commercial opportunity.

Island Pharmaceuticals described Chikungunya as a disease with "significant global health impact," highlighting the lack of broadly accessible antiviral therapies. By securing patent protection explicitly covering Chikungunya alongside flavivirus indications, Island has reinforced the rationale for investigating ISLA-101’s utility in this second major unmet medical need. While the company did not specify plans to initiate clinical development for Chikungunya, the Singapore patent provides a foundation for future work in this area.

Monash University Ownership and Exclusive License to Island Pharmaceuticals

The Singapore patent is owned by Monash University, a leading Australian research institution, and forms part of Island Pharmaceuticals’ exclusively licensed intellectual property portfolio. This licensing arrangement is central to Island’s operations: the company holds exclusive rights to develop and commercialize the underlying intellectual property but does not own the patents outright. The partnership with Monash University is a cornerstone of Island’s asset base and its ability to pursue commercial collaborations.

Exclusive licenses like this are common in pharmaceutical development and provide significant commercial protection if license terms are upheld. Island has emphasized that actively building and safeguarding its intellectual property portfolio is a core strategy to maximize ISLA-101’s long-term value across multiple viral disease indications. Specific terms of the license agreement with Monash University were not disclosed.

Singapore’s Strategic Importance for Dengue and Flavivirus Patent Coverage

Singapore holds a strategic position in the Asia-Pacific region, serving as a major financial and commercial hub and as a jurisdiction where Dengue and other mosquito-borne viral diseases remain endemic. The city-state experiences periodic Dengue outbreaks and maintains active public health surveillance for vector-borne diseases, making it a clinically and commercially relevant market for an antiviral candidate like ISLA-101.

Island’s update highlighted that protection in Singapore "complements Island’s broader intellectual property strategy to secure commercial exclusivity across key territories with high disease prevalence and commercial relevance." For a company targeting the Asia-Pacific region for commercialization, establishing patent coverage in Singapore strengthens its negotiating position with potential regional partners, distributors, and licensees. It also signals a systematic approach to building a multi-jurisdiction intellectual property estate rather than relying on any single territory.

CEO Dr David Foster Highlights Patent’s Commercial Value

Chief Executive Officer and Managing Director Dr David Foster commented on the patent grant, stating: "The grant of this Singapore patent further strengthens the IP supporting ISLA-101 and expands protection in a strategically important region where Dengue and other flavivirus infections remain a significant health challenge." He also noted that maintaining and expanding the patent portfolio is a key part of the company’s strategy to maximize the program’s long-term commercial value.

Dr Foster added that the patent "enhances the exclusivity surrounding ISLA-101 and supports future partnering and commercial opportunities across Asia." The company did not disclose details about any ongoing partnership discussions. Investors may interpret the management’s emphasis on partnering as an indication that out-licensing or co-development arrangements in the Asia-Pacific remain a central component of Island’s forward strategy for ISLA-101.

ISLA-101 Development Context: Addressing Dengue, Flaviviruses, and Unmet Needs

Island describes ISLA-101 as a repurposed compound with a well-established safety profile, under development for prevention and treatment of Dengue fever and other vector-borne diseases. Dengue is among the world’s fastest-spreading vector-borne illnesses, with the World Health Organization estimating that roughly half the global population is at risk. Despite the disease’s scale, approved antiviral treatments are limited, and the market opportunity for a safe, effective antiviral is substantial.

The flavivirus family targeted by ISLA-101 includes Dengue, Zika, Yellow fever, West Nile virus, and others. By securing patent protection covering flavivirus infections broadly, as well as Chikungunya — caused by an alphavirus — Island has positioned ISLA-101 across a wider disease landscape than Dengue alone. The company has not provided a timeline for clinical data readouts in this update but continues to prioritize advancing ISLA-101 through clinical development.

Island’s Dual Antiviral Asset Approach: ISLA-101 and Galidesivir

Island Pharmaceuticals pursues a dual development strategy featuring two core antiviral assets: ISLA-101 and Galidesivir. While ISLA-101 is the focus of this patent news, Galidesivir targets a broad range of RNA viruses. Company materials indicate Galidesivir has demonstrated activity against over 20 RNA viruses, including high-priority pathogens such as Ebola, Marburg, MERS, Zika, and Yellow fever — diseases with significant unmet medical needs and biosecurity implications.

This two-asset portfolio provides diversification within the antiviral space, though both programs remain in clinical or earlier development stages. Island’s focus on diseases with limited or no approved antiviral therapies reflects a deliberate strategy to address gaps in current treatment options. No updates on Galidesivir’s development timeline were provided in this announcement.

Establishing Long-Term Commercial Exclusivity via Multi-Jurisdiction Patent Coverage

The Singapore patent grant is the latest addition to Island’s actively expanding intellectual property estate for ISLA-101. The company stated it "continues to actively build and protect its intellectual property portfolio as a core component of its strategy to maximize the long-term value of ISLA-101 across multiple viral disease indications." This suggests further patent applications or grants in other jurisdictions may be forthcoming, though no specific locations or timelines were mentioned.

For early-stage pharmaceutical companies, a robust, multi-jurisdictional patent portfolio is critical to commercial success. It defines the exclusive operating boundaries for the company and any partners or licensees and is a key consideration in any due diligence by potential commercial collaborators. With the Singapore patent valid until 2034, Island secures approximately eight years of market exclusivity, covering anticipated clinical development and potential commercialization phases if ISLA-101 progresses successfully through regulatory pathways.

Investor Considerations as ISLA-101 Advances Clinically

Investors following Island Pharmaceuticals should note that while intellectual property milestones are important enablers, they typically do not generate immediate value on their own. The commercial and clinical impact of the Singapore patent will depend on ISLA-101’s overall success in clinical trials, regulatory approvals, and market access. No immediate share price reaction was evident from public information at the time of this report.

Key upcoming milestones likely to attract market attention include updates on ISLA-101’s clinical progress, announcements regarding formal partnership or licensing discussions in the Asia-Pacific, and additional patent grants in further jurisdictions. Island’s stated strategy to build commercial exclusivity in territories with high disease prevalence and commercial relevance indicates that further intellectual property developments may be expected. Investors interested in antiviral development and Asia-Pacific health markets should monitor Island Pharmaceuticals’ expanding IP portfolio closely.